Tags:BuildingChemicalPhysical
Ambrx is based on a fundamental advance in protein biosynthesis that enables the company to genetically engineer proteins with new amino acid building blocks beyond the existing 20 natural amino acids, enabling the biosynthesis of proteins with new physical, chemical and pharmacological properties. Ambrx is based in the USA in La Jolla, CA.
Total raised: $200M

Investors 3

Funding Rounds 1

DateSeriesAmountInvestorsDeal News
09.11.2020-$200M-Ambrx Clos...

Mentions in press and media 7

DateTitleDescriptionCategoryAuthorSource
07.01.2021Ambrx Appo... SAN DIEGO, Jan. 7, 2021 /PRN...--prnewswire...
23.11.2020$200M inve...Investors in the $200 million ...--medcitynew...
10.11.2020 Ambrx ...San Diego-based biopharmaceuti...--socaltech....
09.11.2020Ambrx Clos... SAN DIEGO, Nov. 9, 2020 /PRN...--prnewswire...
09.11.2020Ambrx Clos...Ambrx Inc., a San Diego, CA-ba...USA-finsmes.co...
05.08.2016Ambrx Clos...Ambrx, Inc., a San Diego, CA-b...USA-finsmes.co...
06.07.2006 Ambrx ...San Diego-based Ambrx has rais...--socaltech....